dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Tempero, Margaret A. |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Reni, Michele |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Hendifar, Andrew E. |
dc.contributor.author | Macarulla Mercadé, Teresa |
dc.contributor.author | Oh, Do-Youn |
dc.date.accessioned | 2022-06-17T10:54:57Z |
dc.date.available | 2022-06-17T10:54:57Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021 May;32(5):600–8. |
dc.identifier.issn | 0923-7534 |
dc.identifier.uri | https://hdl.handle.net/11351/7711 |
dc.description | Ibrutinib; Adenocarcinoma de pàncrees metastàtic; Fase III |
dc.description.sponsorship | This work was supported by Pharmacyclics LLC, an AbbVie Company (no grant number). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Annals of Oncology;32(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pàncrees - Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Pancreatic Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Treatment Outcome |
dc.title | Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.annonc.2021.01.070 |
dc.subject.decs | neoplasias pancreáticas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1016/j.annonc.2021.01.070 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Tempero M] Department of Medicine, University of California San Francisco, San Francisco, USA. [Oh DY] Department of Internal Medicine, Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. [Tabernero J, Macarulla T] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UICC, CIBERONC, Barcelona, Spain. [Reni M] Department of Radiochemotherapy, San Raffaele Hospital Scientific Institute, Milan, Italy. [Van Cutsem E] Department of Digestive Oncology, University Hospitals Gasthuisberg/Leuven & KU Leuven, Leuven, Belgium. [Hendifar A] Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, USA |
dc.identifier.pmid | 33539945 |
dc.identifier.wos | 000640355800006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |